Dosimetric coverage of the prostate, normal tissue sparing, and acute XXXX with @entity1168 brachytherapy for large prostate volumes.

@entity1 @entity137 @entity263 @entity4272 @entity342 @entity1168
PURPOSE: To evaluate dosimetric coverage of the prostate, normal tissue sparing, and acute @entity137 with @entity1168 brachytherapy for large prostate volumes. MATERIALS AND METHODS: One hundred and two @entity263 @entity1 with prostate volumes >50 mL (range: 5-29 mL) were treated with @entity1168 ( @entity1168 ) brachytherapy    intensity modulated radiation therapy (IMRT) to 4,500 cGy in 25 daily fractions between 2009 and 2013. @entity1168 brachytherapy monotherapy doses consisted of two 1,350-1,400 cGy fractions separated by 2-3 weeks, and @entity1168 brachytherapy boost doses consisted of two 950-1,150 cGy fractions separated by 4 weeks. Twelve of 32 (38%) unfavorable intermediate risk, high risk, and very high risk @entity1 received @entity342 deprivation therapy. Acute @entity137 was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4. RESULTS: Median follow-up was 14 months. Dosimetric goals were achieved in over 90% of cases. Three of 102 (3%) @entity1 developed Grade 2 acute @entity4272 . No variables were significantly associated with Grade 2 acute @entity4272 . Seventeen of 102 (17%) @entity1 developed Grade 2 acute urinary retention. American Urological Association (AUA) symptom score was the only variable significantly associated with Grade 2 acute urinary retention (p=0.04). There was no >=  Grade 3 acute @entity137 . CONCLUSIONS: Dosimetric coverage of the prostate and normal tissue sparing were adequate in @entity1 with prostate volumes >50 mL. Higher pre-treatment AUA symptom scores increased the relative risk of Grade 2 acute urinary retention. However, the overall incidence of acute @entity137 was acceptable in @entity1 with large prostate volumes.
